Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 91.64% | 6.58% | 5.03% | 3.56% | -63.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.64% | 6.58% | 5.03% | 3.56% | -63.75% |
| Cost of Revenue | 83.12% | 28.24% | -0.31% | -19.49% | -140.42% |
| Gross Profit | 38.97% | -5.80% | 8.04% | 20.44% | -15.36% |
| SG&A Expenses | -14.25% | -13.99% | -7.55% | 1.26% | 34.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.05% | -14.12% | -17.74% | -15.16% | -10.18% |
| Operating Income | 58.71% | 39.56% | 50.54% | 37.59% | -71.60% |
| Income Before Tax | -29.60% | 74.61% | 32.67% | 13.21% | -297.48% |
| Income Tax Expenses | -107.79% | -- | -- | -- | 25.53% |
| Earnings from Continuing Operations | -19.92% | 74.61% | 32.67% | 13.21% | -758.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.92% | 74.61% | 32.67% | 13.21% | -758.15% |
| EBIT | 58.71% | 39.56% | 50.54% | 37.59% | -71.60% |
| EBITDA | 60.95% | 41.58% | 53.83% | 40.68% | -71.46% |
| EPS Basic | -2.05% | 79.30% | 45.42% | 30.11% | -702.27% |
| Normalized Basic EPS | -7.01% | 79.43% | 47.65% | 30.15% | -345.57% |
| EPS Diluted | -2.05% | 79.30% | 45.42% | 30.11% | -702.27% |
| Normalized Diluted EPS | -7.01% | 79.43% | 47.65% | 30.15% | -345.57% |
| Average Basic Shares Outstanding | 17.53% | 22.71% | 23.38% | 24.24% | 6.68% |
| Average Diluted Shares Outstanding | 17.53% | 22.71% | 23.38% | 24.24% | 6.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |